Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2025 Filed Feb 13, 2025 16:59 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
GrantNon-qualified Stock Options · Derivative | 2,100 | $0.00 Strike: $245.14 | $0.00 |
DisclosureSEC source: 0001127602-25-004556 · form4.xml · derivative · entry 3 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,100 Underlying: Common Stock · 2,100 shares Expires 2035-02-10 F3 · security: Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan. F4 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:59 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
Tax withholdingCommon Stock | 55 | $245.14 | $13,482.70 |
DisclosureSEC source: 0001127602-25-004556 · form4.xml · nonDerivative · entry 2 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,770.5 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:59 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
Exercise / conversionCommon Stock | 201 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-004556 · form4.xml · nonDerivative · entry 1 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,825.5 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:50 UTC |
Bailey Megan D.EVP, Pres, Central Labs & Intl
|
GrantRestricted Stock Unit · Derivative | 1,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004544 · form4.xml · derivative · entry 2 Bailey Megan D. · CIK 0001975682 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,256 Underlying: Common Stock · 1,210 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2026. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2026. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:50 UTC |
Bailey Megan D.EVP, Pres, Central Labs & Intl
|
GrantNon-qualified Stock Options · Derivative | 3,700 | $0.00 Strike: $245.14 | $0.00 |
DisclosureSEC source: 0001127602-25-004544 · form4.xml · derivative · entry 1 Bailey Megan D. · CIK 0001975682 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,700 Underlying: Common Stock · 3,700 shares Expires 2035-02-10 F1 · security: Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan. F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:49 UTC |
Schechter Adam HDirector · President & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,963 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004543 · form4.xml · derivative · entry 6 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,139 Underlying: Common Stock · 2,963 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F8 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 11, 2023 and are now fully vested. F8 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 11, 2023 and are now fully vested. F7 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:49 UTC |
Schechter Adam HDirector · President & CEO
|
GrantRestricted Stock Unit · Derivative | 10,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004543 · form4.xml · derivative · entry 5 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,102 Underlying: Common Stock · 10,970 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2026. F6 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2026. F7 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:49 UTC |
Schechter Adam HDirector · President & CEO
|
GrantNon-qualified Stock Options · Derivative | 33,100 | $0.00 Strike: $245.14 | $0.00 |
DisclosureSEC source: 0001127602-25-004543 · form4.xml · derivative · entry 4 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,100 Underlying: Common Stock · 33,100 shares Expires 2035-02-10 F4 · security: Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:49 UTC |
Schechter Adam HDirector · President & CEO
|
Tax withholdingCommon Stock | 1,226 | $245.14 | $300,541.64 |
DisclosureSEC source: 0001127602-25-004543 · form4.xml · nonDerivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,182 F3 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:49 UTC |
Schechter Adam HDirector · President & CEO
|
Exercise / conversionCommon Stock | 2,963 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-004543 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:49 UTC |
Schechter Adam HDirector · President & CEO
|
SaleCommon Stock | 6,121 | $244.62 | $1,497,319.02 |
DisclosureSEC source: 0001127602-25-004543 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,445 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:39 UTC |
EISENBERG GLENN AExecutive Vice President
|
Exercise / conversionRestricted Stock Unit · Derivative | 807 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004540 · form4.xml · derivative · entry 3 EISENBERG GLENN A · CIK 0001222831 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,819 Underlying: Common Stock · 807 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 11, 2023 and are now fully vested. F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 11, 2023 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:39 UTC |
EISENBERG GLENN AExecutive Vice President
|
Tax withholdingCommon Stock | 213 | $245.14 | $52,214.82 |
DisclosureSEC source: 0001127602-25-004540 · form4.xml · nonDerivative · entry 2 EISENBERG GLENN A · CIK 0001222831 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,245 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:39 UTC |
EISENBERG GLENN AExecutive Vice President
|
Exercise / conversionCommon Stock | 807 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-004540 · form4.xml · nonDerivative · entry 1 EISENBERG GLENN A · CIK 0001222831 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:36 UTC |
BERBERIAN LANCEEVP, Special Advisor, Strategy
|
Exercise / conversionRestricted Stock Unit · Derivative | 323 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004539 · form4.xml · derivative · entry 3 BERBERIAN LANCE · CIK 0001102900 · EVP, Special Advisor, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,067 Underlying: Common Stock · 323 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 11, 2023 and are now fully vested. F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 11, 2023 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:36 UTC |
BERBERIAN LANCEEVP, Special Advisor, Strategy
|
Tax withholdingCommon Stock | 86 | $245.14 | $21,082.04 |
DisclosureSEC source: 0001127602-25-004539 · form4.xml · nonDerivative · entry 2 BERBERIAN LANCE · CIK 0001102900 · EVP, Special Advisor, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,680 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:36 UTC |
BERBERIAN LANCEEVP, Special Advisor, Strategy
|
Exercise / conversionCommon Stock | 323 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-004539 · form4.xml · nonDerivative · entry 1 BERBERIAN LANCE · CIK 0001102900 · EVP, Special Advisor, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,766 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:34 UTC |
Caveney Brian JEVP, Pres of ED, CMO & CSO
|
Exercise / conversionRestricted Stock Unit · Derivative | 473 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004538 · form4.xml · derivative · entry 5 Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,188 Underlying: Common Stock · 473 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 11, 2023 and are now fully vested. F7 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 11, 2023 and are now fully vested. F6 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:34 UTC |
Caveney Brian JEVP, Pres of ED, CMO & CSO
|
GrantRestricted Stock Unit · Derivative | 2,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004538 · form4.xml · derivative · entry 4 Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,661 Underlying: Common Stock · 2,220 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2026. F5 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2026. F6 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:34 UTC |
Caveney Brian JEVP, Pres of ED, CMO & CSO
|
GrantNon-qualified Stock Options · Derivative | 6,700 | $0.00 Strike: $245.14 | $0.00 |
DisclosureSEC source: 0001127602-25-004538 · form4.xml · derivative · entry 3 Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,700 Underlying: Common Stock · 6,700 shares Expires 2035-02-10 F3 · security: Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan. F4 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:34 UTC |
Caveney Brian JEVP, Pres of ED, CMO & CSO
|
Tax withholdingCommon Stock | 136 | $245.14 | $33,339.04 |
DisclosureSEC source: 0001127602-25-004538 · form4.xml · nonDerivative · entry 2 Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,335.6573 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:34 UTC |
Caveney Brian JEVP, Pres of ED, CMO & CSO
|
Exercise / conversionCommon Stock | 473 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-004538 · form4.xml · nonDerivative · entry 1 Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,471.6573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:31 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 323 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004537 · form4.xml · derivative · entry 5 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,257 Underlying: Common Stock · 323 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 11, 2023 and are now fully vested. F7 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 11, 2023 and are now fully vested. F6 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:31 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
GrantRestricted Stock Unit · Derivative | 1,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004537 · form4.xml · derivative · entry 4 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,580 Underlying: Common Stock · 1,130 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2026. F5 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2026. F6 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:31 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
GrantNon-qualified Stock Options · Derivative | 3,400 | $0.00 Strike: $245.14 | $0.00 |
DisclosureSEC source: 0001127602-25-004537 · form4.xml · derivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,400 Underlying: Common Stock · 3,400 shares Expires 2035-02-10 F3 · security: Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan. F4 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:31 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Tax withholdingCommon Stock | 86 | $245.14 | $21,082.04 |
DisclosureSEC source: 0001127602-25-004537 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,484.5397 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:31 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 323 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-004537 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,570.5397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:30 UTC |
Schroeder Mark SEVP, Pres Diagnostics & COO
|
Exercise / conversionRestricted Stock Unit · Derivative | 473 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004536 · form4.xml · derivative · entry 5 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,588 Underlying: Common Stock · 473 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 11, 2023 and are now fully vested. F7 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 11, 2023 and are now fully vested. F6 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:30 UTC |
Schroeder Mark SEVP, Pres Diagnostics & COO
|
GrantRestricted Stock Unit · Derivative | 2,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004536 · form4.xml · derivative · entry 4 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,061 Underlying: Common Stock · 2,420 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2026. F5 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2026. F6 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:30 UTC |
Schroeder Mark SEVP, Pres Diagnostics & COO
|
GrantNon-qualified Stock Options · Derivative | 7,300 | $0.00 Strike: $245.14 | $0.00 |
DisclosureSEC source: 0001127602-25-004536 · form4.xml · derivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,300 Underlying: Common Stock · 7,300 shares Expires 2035-02-10 F3 · security: Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan. F4 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:30 UTC |
Schroeder Mark SEVP, Pres Diagnostics & COO
|
Tax withholdingCommon Stock | 134 | $245.14 | $32,848.76 |
DisclosureSEC source: 0001127602-25-004536 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,396.1426 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:30 UTC |
Schroeder Mark SEVP, Pres Diagnostics & COO
|
Exercise / conversionCommon Stock | 473 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-004536 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,530.1426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:28 UTC |
GRAHAM ANITA ZEVP, CHRO
|
GrantRestricted Stock Unit · Derivative | 1,070 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004535 · form4.xml · derivative · entry 2 GRAHAM ANITA Z · CIK 0001206814 · EVP, CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,091 Underlying: Common Stock · 1,070 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2026. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2026. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:28 UTC |
GRAHAM ANITA ZEVP, CHRO
|
GrantNon-qualified Stock Options · Derivative | 3,200 | $0.00 Strike: $245.14 | $0.00 |
DisclosureSEC source: 0001127602-25-004535 · form4.xml · derivative · entry 1 GRAHAM ANITA Z · CIK 0001206814 · EVP, CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,200 Underlying: Common Stock · 3,200 shares Expires 2035-02-10 F1 · security: Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan. F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:19 UTC |
Oyegunwa AkinboladeEVP, CIO & CTO
|
Exercise / conversionRestricted Stock Unit · Derivative | 134 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004532 · form4.xml · derivative · entry 5 Oyegunwa Akinbolade · CIK 0002042869 · EVP, CIO & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,309 Underlying: Common Stock · 134 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 11, 2023 and are now fully vested. F7 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 11, 2023 and are now fully vested. F6 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:19 UTC |
Oyegunwa AkinboladeEVP, CIO & CTO
|
GrantRestricted Stock Unit · Derivative | 690 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004532 · form4.xml · derivative · entry 4 Oyegunwa Akinbolade · CIK 0002042869 · EVP, CIO & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,443 Underlying: Common Stock · 690 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2026. F5 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2026. F6 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:19 UTC |
Oyegunwa AkinboladeEVP, CIO & CTO
|
GrantNon-qualified Stock Options · Derivative | 2,100 | $0.00 Strike: $245.14 | $0.00 |
DisclosureSEC source: 0001127602-25-004532 · form4.xml · derivative · entry 3 Oyegunwa Akinbolade · CIK 0002042869 · EVP, CIO & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,100 Underlying: Common Stock · 2,100 shares Expires 2035-02-10 F3 · security: Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan. F4 · derivative.exercise_date: The option vests in three equal installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:19 UTC |
Oyegunwa AkinboladeEVP, CIO & CTO
|
Tax withholdingCommon Stock | 42 | $245.14 | $10,295.88 |
DisclosureSEC source: 0001127602-25-004532 · form4.xml · nonDerivative · entry 2 Oyegunwa Akinbolade · CIK 0002042869 · EVP, CIO & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,974.253 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:19 UTC |
Oyegunwa AkinboladeEVP, CIO & CTO
|
Exercise / conversionCommon Stock | 134 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-004532 · form4.xml · nonDerivative · entry 1 Oyegunwa Akinbolade · CIK 0002042869 · EVP, CIO & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,016.253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:18 UTC |
Wang Julia AijunChief Financial Officer, EVP
|
GrantRestricted Stock Unit · Derivative | 2,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004529 · form4.xml · derivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,367 Underlying: Common Stock · 2,580 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2026. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2026. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:18 UTC |
Wang Julia AijunChief Financial Officer, EVP
|
GrantNon-qualified Stock Options · Derivative | 7,800 | $0.00 Strike: $245.14 | $0.00 |
DisclosureSEC source: 0001127602-25-004529 · form4.xml · derivative · entry 1 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2035-02-10 F1 · security: Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan. F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 13:26 UTC |
Rothman PaulDirector
|
GrantRestricted Stock Unit · Derivative | 897 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004520 · form4.xml · derivative · entry 1 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 897 Underlying: Common Stock · 897 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2026. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2026. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 13:27 UTC |
Wengel Kathryn EDirector
|
GrantRestricted Stock Unit · Derivative | 897 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004521 · form4.xml · derivative · entry 1 Wengel Kathryn E · CIK 0001745955 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 897 Underlying: Common Stock · 897 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2026. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2026. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 13:25 UTC |
Parham Richelle PDirector
|
GrantRestricted Stock Unit · Derivative | 897 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004519 · form4.xml · derivative · entry 1 Parham Richelle P · CIK 0001550078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 897 Underlying: Common Stock · 897 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2026. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2026. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 13:24 UTC |
NEUPERT PETER MDirector
|
GrantRestricted Stock Unit · Derivative | 897 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004518 · form4.xml · derivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 897 Underlying: Common Stock · 897 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2026. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2026. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 13:23 UTC |
Kong GarhengDirector
|
GrantRestricted Stock Unit · Derivative | 897 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004517 · form4.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 897 Underlying: Common Stock · 897 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2026. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2026. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 13:22 UTC |
Gilliland Dwight GaryDirector
|
GrantRestricted Stock Unit · Derivative | 897 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004516 · form4.xml · derivative · entry 1 Gilliland Dwight Gary · CIK 0001603769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 897 Underlying: Common Stock · 897 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2026. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2026. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 13:21 UTC |
Davis Jeffrey A.Director
|
GrantRestricted Stock Unit · Derivative | 897 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004515 · form4.xml · derivative · entry 1 Davis Jeffrey A. · CIK 0001648477 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 897 Underlying: Common Stock · 897 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2026. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2026. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 13:19 UTC |
ANDERSON KERRII BDirector
|
GrantRestricted Stock Unit · Derivative | 897 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004514 · form4.xml · derivative · entry 1 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 897 Underlying: Common Stock · 897 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2026. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2026. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 13:17 UTC |
Kliphouse Kirsten MarieDirector
|
GrantRestricted Stock Unit · Derivative | 897 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004513 · form4.xml · derivative · entry 1 Kliphouse Kirsten Marie · CIK 0001948684 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 897 Underlying: Common Stock · 897 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. ("LHI") Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2026. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.